Non-treated RA Group NO 35 ( M ± SD ) |
RAsero- NO 18 ( M ± SD ) |
RAsero+ NO 17 ( M ± SD ) |
Control healthy group NO 35 ( M ± SD ) |
|
Positive/ negative | Positive/ negative | Positive/ negative | Positive/ negative | |
ADMA + > 0.75 (micromol/L ) |
13/22 1,096 (± 0,68) (0,25-3,1) |
9/9 1,12 (± 0,58) (0,32-2,1) |
4/13 1,07 (± 0,79) (0,25-3,1) |
8/27 1,00 (± 0,50) (0,26-1,91) |
RF + 30 ≥ IU/ml |
17/18 346,15 (± 625,22 ) (0,00-1920) |
0/18 0,00 (± 0,00 ) (0,00-0,00) |
17/0 712,67 (± 743,72 ) (30-1920) |
2/33 13,71 (± 38,73 ) (0,00-120) |
CRP + 12 ≥ mg/L |
14/21 46,86 (± 79,19 ) (0,00-384) |
3/15 8,66 (± 24,62 ) (0,00-96) |
13/4 87,31 (± 96,44 ) (0,00-384) |
4/31 5,48 (± 12,80 ) (0,00-48) |
ESR + ≥ 16 | 27/8 48,62 (± 39,81 ) (2,0-120) |
13/5 43,94 (± 39,82 ) (2,0-120) |
14/3 53,58 (± 40,39 ) (5,0-120) |
4/31 9,42 (± 8,21 ) (2,0-44) |
ACPA antibodies + ≥ 1,26 |
23/12 1,71 (± 0,69 ) (0,92-3,0) |
11/7 1,56 (± 0,59 ) (0,93-2,6) |
12/5 1,87 (± 0,77 ) (0,92-3,0) |
1/34 0,95 (± 0,10 ) (0,90-1,38) |
DAS 28 + ≥ 3,2 |
28/7 4,79 (± 1,56 ) (1,85-7,03) |
13/5 4,56 (± 1,76 ) (1,85-7,03) |
15/2 5,04 (± 1,33 ) (2,47-6,83) |
0/35 0,00 (± 0,00 ) (0,00-0,00) |
Morning stiffness + > 0 min |
26/9 43,20 (± 65,13 ) ( 0-300 ) |
14/4 57,50 (± 81,40 ) (0-300) |
12/5 28,05 (± 38,72 ) (0-120) |
0/35 0,00 (± 0,00 ) (0,00-0,00) |